Skip to main content

Advertisement

Log in

Cystinosis: the evolution of a treatable disease

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Cystinosis is a rare autosomal recessive disorder involving lysosomal storage of the amino acid cystine due to a defect in the membrane transport protein, cystinosin. Since the introduction of kidney transplants and the availability of cystine-depleting medical therapy, this previously fatal disease was transformed into a treatable disorder. Renal allografts and medical therapy targeting the basic metabolic defect have altered the natural hisotry of cystinosis so drastically that patients have a life expectancy extending past 50 years. Consequently, early diagnosis and appropriate therapy are critically important. In this article, we offer a review of the manifestations of cystinosis, including the proximal tubular dysfunction of renal Fanconi syndrome, and discuss the prevention and treatment of the disorder’s systemic complications. We focus on the nephropathic forms of cystinosis, aiming to assist nephrologists and other physicians to develop early recognition and appropriate management of cystinosis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Drube J, Schiffer E, Mischak H, Kemper MJ, Neuhaus T, Pape L, Lichtinghagen R, Ehrich JH (2009) Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 24(7):2161–2169

    Article  PubMed  CAS  Google Scholar 

  2. Gahl WA, Thoene JG, Schneider JA (2002) Cystinosis. N Engl J Med 1347:111–121

    Article  Google Scholar 

  3. Anikster Y, Lucero C, Touchman JW, Huizing M, McDowell G, Shotelersuk V, Green ED, Gahl WA (1999) Identification and detection of the common 65-kb deletion breakpoint in the nephropathic cystinosis gene (CTNS). Mol Genet Metab 66:111–116

    Article  PubMed  CAS  Google Scholar 

  4. Gahl WA, Thoene J, Schneider JA (2001) Cystinosis: a disorder of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B. (eds) The metabolic and molecular basis of inherited disease, Eighth edition. McGraw-Hill Companies, Inc, pp. 5085-5108

  5. Kalatzis V, Antignac C (2002) Cystinosis: from gene to disease. Nephrol Dial Transplant 17:1883–1886

    Article  PubMed  CAS  Google Scholar 

  6. Anikster Y, Lacbawan F, Brantly M, Gochuico BL, Avila NA, Travis W, Gahl WA (2001) Pulmonary dysfunction in adults with nephropathic cystinosis. Chest 119:394–401

    Article  PubMed  CAS  Google Scholar 

  7. Thoene J, Lemons R, Anikster Y, Mullet J, Paelicke K, Lucero C, Gahl W, Schneider J, Shu SG, Campbell HT (1999) Mutations of CTNS causing intermediate cystinosis. Mol Genet Metab 7:283–289

    Article  Google Scholar 

  8. Nesterova G, Gahl WA (2009) Cystinosis, Genereviews website: www.ncbi.nlm.nih.gov›Bookshelf

  9. Gahl WA, Thoene JG, Schneider JA, O’Regan S, Kaiser-Kupfer MI, Kuwabara T (1988) NIH conference - Cystinosis: progress in a prototypic disease. Ann Intern Med 109:557–569

    PubMed  CAS  Google Scholar 

  10. Pisoni RL, Thoene JG, Christensen HN (1985) Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts: role in therapeutic cystine removal. J Biol Chem 260:4791–4798

    PubMed  CAS  Google Scholar 

  11. Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD (1982) Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 217:1263–1265

    Article  PubMed  CAS  Google Scholar 

  12. Park M, Helip-Wooley A, Thoene J (2002) Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J Am Soc Nephrol 13:2878–2887

    Article  PubMed  CAS  Google Scholar 

  13. Thoene JG (2007) A review of the role of enhanced apoptosis in the pathophysiology of cystinosis. Mol Genet Metab 92(4):292–298

    Article  PubMed  CAS  Google Scholar 

  14. Sansanwal P, Yen B, Gahl WA, Ma Y, Ying L, Wong LJ, Sarwal MM (2010) Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis. J Am Soc Nephrol 21(2):272–283

    Article  PubMed  CAS  Google Scholar 

  15. Park M, Thoene J (2005) Potential role of apoptosis in development of the cystinotic phenotype. Pediatr Nephrol 20:441–446

    Article  PubMed  Google Scholar 

  16. Larsen CP, Walker PD, Thoene JG (2010) The incidence of atubular glomeruli in nephropathic cystinosis renal biopsies. Mol Genet Metab 101(4):417–420

    Article  PubMed  CAS  Google Scholar 

  17. Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot MO, Gogat K, Abitbol M, Broyer M, Gubler MC, Antignac C (2002) Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol Cell Bio 22:7622–7632

    Article  CAS  Google Scholar 

  18. Baum M (1998) The Fanconi syndrome of cystinosis: insights into the pathophysiology. Pediatr Nephrol 12:492–497

    Article  PubMed  CAS  Google Scholar 

  19. Roth KS, Foreman JW, Segal S (1981) The Fanconi syndrome and mechanisms of tubular transport dysfunction. Kidney Int 20:705–716

    Article  PubMed  CAS  Google Scholar 

  20. Baum M (1993) The cellular basis of Fanconi syndrome. Hosp Pract (Off Ed) 28(11):137–142, Review 147-148

    CAS  Google Scholar 

  21. Theodoropoulos DS, Shawker TH, Heinrichs C, Gahl WA (1995) Medullary nephrocalcinosis in nephropathic cystinosis. Pediatr Nephrol 9:412–418

    Article  PubMed  CAS  Google Scholar 

  22. Winkler L, Offner G, Krull F, Brodehl J (1993) Growth and pubertal development in nephropathic cystinosis. Eur J Pediatr 152:244–249

    Article  PubMed  CAS  Google Scholar 

  23. Bernardini I, Rizzo WB, Dalakas M, Bernar J, Gahl WA (1985) Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 75:1124–1130

    Article  PubMed  CAS  Google Scholar 

  24. Long WS, Seashore MR, Siegel NJ, Bia MJ (1990) Idiopathic Fanconi syndrome with progressive renal failure: a case report and discussion. Yale J Biol Med 63(1):15–28

    PubMed  CAS  Google Scholar 

  25. Cetinkaya I, Schlatter E, Hirsch JR, Herter P, Harms E, Kleta R (2002) Inhibition of Na+-dependent transporters in cystine-loaded human renal cells: electrophysiological studies on the Fanconi syndrome of cystinosis. J Am Soc Nephrol 13:2085–2093

    Article  PubMed  CAS  Google Scholar 

  26. Manz F, Gretz N (1994) Progression of chronic renal failure in a historical group of patients with nephropathic cystinosis. European Collaborative Study on Cystinosis. Pediatr Nephrol 8:466–471

    Article  PubMed  CAS  Google Scholar 

  27. Middleton R, Bradbury M, Webb N, O’Donoghue D, van’t Hoff W (2003) Cystinosis. A clinicopathological conference. “From toddlers to twenties and beyond” Adult-Paediatric Nephrology Interface Meeting, Manchester 2001. Nephrol Dial Transplant 18:2492–2495

    Article  PubMed  Google Scholar 

  28. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI (2000) Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 71:100–120

    Article  PubMed  CAS  Google Scholar 

  29. Gahl WA (1986) Cystinosis coming of age. Adv Pediatr 33:95–126

    PubMed  CAS  Google Scholar 

  30. Gahl WA, Hubbard VS, Orloff S (1984) Decreased sweat production in cystinosis. J Pediatr 104:904–905

    Article  PubMed  CAS  Google Scholar 

  31. Chik CL, Friedman A, Merriam GR, Gahl WA (1993) Pituitary testicular function in nephropathic cystinosis. Ann Intern Med 119:568–575

    PubMed  CAS  Google Scholar 

  32. Dogulu CF, Tsilou E, Rubin B, Fitzgibbon EJ, Kaiser-Kupper MI, Rennert OM, Gahl WA (2004) Idiopathic intracranial hypertension in cystinosis. J Pediatr 145(5):673–678

    Article  PubMed  Google Scholar 

  33. Broyer M, Tete MJ, Guest G, Bertheleme JP, Labrousse F, Poisson M (1996) Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine. J Inherit Metab Dis 19:65–75

    Article  PubMed  CAS  Google Scholar 

  34. Ballantyne AO, Trauner DA (2000) Neurobehavioral consequences of a genetic metabolic disorder: visual processing deficits in infantile nephropathic cystinosis. Neuropsychiatr Neuropsychol Behav Neurol 13:254–263

    CAS  Google Scholar 

  35. Nesterova G, Gahl W (2008) Nephropathic cystinosis: late complications of a multisystemic disease. Pediatr Nephrol 23(6):863–867

    Article  PubMed  Google Scholar 

  36. Wühl E, Haffner D, Offner G, Broyer M, van’t Hoff W, Mehls O, European Study Group on Growth Hormone Treatment in Children with Nephropathic Cystinosis (2001) Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr 138:880–887

    Article  PubMed  Google Scholar 

  37. Schnaper HW, Cottel J, Merrill S, Marcusson E, Kissane JM, Shackelford GD, So SK, Nelson RD, Cole BR, Smith ML, Schneider JA (1992) Early occurrence of end-stage renal disease in a patient with infantile nephropathic cystinosis. J Pediatr 120(4 Pt 1):575–578

    PubMed  CAS  Google Scholar 

  38. Mahoney CP, Striker GE (2000) Early development of the renal lesions in infantile cystinosis. Pediatr Nephrol 15:50–56

    Article  PubMed  CAS  Google Scholar 

  39. Gahl WA, Balog JZ, Kleta R (2007) Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intl Med 147(4):242–250

    Google Scholar 

  40. Almond PS, Matas AJ, Nakhleh RE, Morel P, Troppmann C, Najarian JS, Chavers B (1993) Renal transplantation for infantile cystinosis: long-term follow-up. J Pediatr Surg 28:232–238

    Article  PubMed  CAS  Google Scholar 

  41. Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman CB, Leonard MB, Mannon RB, Sarwal M, Schneider JA, Skovby F, Sonies BC, Thoene JG, Trauner DA, Gahl WA, NIH Office of Rare Diseases (2005) First NIH/Office of Rare Diseases Conference on cystinosis: past, present, and future. Pediatr Nephrol 20:452–454

    Article  PubMed  Google Scholar 

  42. Kleta R, Bernardini I, Ueda M, Varade WS, Phornphutkul C, Krasnewich D, Gahl WA (2004) Long-term follow-up of well treated nephropathic cystinosis patients. J Pediatr 145:555–560

    Article  PubMed  Google Scholar 

  43. Markello TC, Bernardini IM, Gahl WA (1993) Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328:1157–1162

    Article  PubMed  CAS  Google Scholar 

  44. Tsilou ET, Rubin BI, Reed G, Caruso RC, Iwata F, Balog J, Gahl WA, Kaiser-Kupfer MI (2006) Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. Ophthalmology 113:1002–1009

    Article  PubMed  Google Scholar 

  45. Charnas LR, Luciano CA, Dalakas M, Gilliatt RW, Bernardini I, Ishak K, Cwik VA, Fraker D, Brushart TA, Gahl WA (1994) Distal vacuolar myopathy in nephropathic cystinosis. Ann Neurol 35(2):181–188

    Article  PubMed  CAS  Google Scholar 

  46. Trauner DA, Fahmy RF, Mishler DA (2001) Oral motor dysfunction and feeding difficulties in nephropathic cystinosis. Pediatr Neurol 24:365–368

    Article  PubMed  CAS  Google Scholar 

  47. Zimakas PJ, Sharma AK, Rodd CJ (2003) Osteopenia and fractures in cystinotic children post renal transplantation. Pediatr Nephrol 18:384–390

    PubMed  Google Scholar 

  48. Sonies BC, Almajid P, Kleta R, Bernardini I, Gahl WA (2005) Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy. Med (Baltimore) 84:137–146

    Article  CAS  Google Scholar 

  49. O’Brien K, Hussain N, Warady BA, Kleiner DE, Kleta R, Bernardini I, Heller T, Gahl WA (2006) Nodular regenerative hyperplasia and severe portal hypertension in cystinosis. Clin Gastroenterol Hepatol 4:387–394

    Article  PubMed  Google Scholar 

  50. Treem WR, Rusnack EJ, Ragsdale BD, Seikaly MG, DiPalma JS (1988) Inflammatory bowel disease in a patient with nephropathic cystinosis. Pediatrics 81:584–587

    PubMed  CAS  Google Scholar 

  51. Robert JJ, Tête MJ, Guest G, Gagnadoux MF, Niaudet P, Broyer M (1999) Diabetes mellitus in patients with infantile cystinosis after renal transplantation. Pediatr Nephrol 13(6):524–529

    Article  PubMed  CAS  Google Scholar 

  52. Broyer M, Guillot M, Gubler MC, Habib R (1981) Infantile cystinosis: a reappraisal of early and late symptoms. Adv Nephrol Necker Hosp 10:137–166

    PubMed  CAS  Google Scholar 

  53. Dixit MP, Greifer I (2002) Nephropathic cystinosis associated with cardiomyopathy: a 27-year clinical follow-up. BMC Nephrol 3:8

    Article  PubMed  Google Scholar 

  54. Ueda M, O’Brien K, Rosing D, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl W (2006) Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol 1:555–562

    Article  PubMed  Google Scholar 

  55. Hulton SA, Keffler S, Green A, Taylor CM (1994) Serum cholesterol in children with cystinosis. Abstracts of 32nd Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Edinburgh pg 108

  56. Olgar S, Nisli K, Dindar A, Omeroglu RE, Ertugrul T (2006) Can cystinosis cause coronary artery dilatation? Pediatr Cardiol 27:263–268

    Article  PubMed  CAS  Google Scholar 

  57. Olcay L, Erdemli E, KesimerM BY, Okur H, Kalkanoðlu HS, Coskun T, Altay C (2005) High cystine in platelets from patients with nephropathic cystinosis: a chemical, ultrastructural, and functional evaluation. J Clin Pathol 58:939–945

    Article  PubMed  CAS  Google Scholar 

  58. Quinn JP, Royston D, Murphy PT (2004) Bone marrow findings in hereditary cystinosis with renal failure. Am J Hematol 76:79

    Article  PubMed  CAS  Google Scholar 

  59. Lucky AW, Howley PM, Megyesi K, Spielberg SP, Schulman JD (1977) Endocrine studies in cystinosis: compensated primary hypothyroidism. J Pediatr 91:204–210

    Article  PubMed  CAS  Google Scholar 

  60. Kleta R, Gahl WA (2002) Cystinosis: antibodies and healthy bodies. J Am Soc Nephrol 13:2189–2191

    Article  PubMed  Google Scholar 

  61. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA (1987) Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 316:971–977

    Article  PubMed  CAS  Google Scholar 

  62. Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman CB, Leonard MB, Mannon RB, Sarwal M, Schneider JA, Skovby F, Sonies BC, Thoene JG, Trauner DA, Gahl WA (2005) First NIH/office of rare diseases conference on cystinosis: past, present, and future. Pediatr Nephrol 20(4):452–454

    Article  PubMed  Google Scholar 

  63. Kleta R, Gahl WA (2004) Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother 5:2255–2262

    Article  PubMed  CAS  Google Scholar 

  64. Vilaseca MA, Camacho JA, Briones P, Farré C, Mas A (1995) Biochemical follow-up in late-treated nephropathic cystinosis. J Inherit Metab Dis 18:147–150

    Article  PubMed  CAS  Google Scholar 

  65. Theodoropoulos DS, Krasnewich D, Kaiser-Kupfer MI, Gahl WA (1993) Classic nephropathic cystinosis as an adult disease. JAMA 270:2200–2204

    Article  PubMed  CAS  Google Scholar 

  66. Gahl WA, Schneider JA, Schulman JD, Thoene JG, Reed GF (1990) Predicted reciprocal serum creatinine at age 10 years as a measure of renal function in children with nephropathic cystinosis treated with oral cysteamine. Pediatr Nephrol 4:129–135

    Article  PubMed  CAS  Google Scholar 

  67. Attard M, Jean G, Forestier L, Cherqui S, van’t Hoff W, Broyer M, Antignac C, Town M (1999) Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet 8:2507–2514

    Article  PubMed  CAS  Google Scholar 

  68. Syres K, Harrison F, Tadlock M, Jester JV, Simpson J, Roy S, Salomon DR, Cherqui S (2009) Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood 114(12):2542–2552

    Article  PubMed  CAS  Google Scholar 

  69. Haase M, Morgera S, Bamberg C, Halle H, Martini S, Dragun D, Neumayer H-H, Budde K (2006) Successful pregnancies in dialysis patients including those suffering from cystinosis and familial Mediterranean fever. J Nephrol 19:677–681

    PubMed  CAS  Google Scholar 

  70. Beckman DA, Mullin JJ, Assadi FK (1998) Developmental toxicity of cysteamine in the rat: effects on embryo-fetal development. Teratology 58:96–102

    Article  PubMed  CAS  Google Scholar 

  71. Gahl WA (1997) Consultation with the Specialist: nephropathic cystinosis. Pediatr Rev 18:302–304

    Article  PubMed  CAS  Google Scholar 

  72. Goodyer P (2011) The history of cystinosis: lessons for clinical management Int. J Nephrol. doi:10.4061/2011/929456

  73. Brodin-Sartorius A, Tête MJ, Niaudet P, Antignac C, Guest G, Ottolenghi C, Charbit M, Moyse D, Legendre C, Lesavre P, Cochat P (2012) Servais ACysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 81(2):179–189

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Galina Nesterova.

Additional information

Answers:

1)4.

2)4.

3)3.

4)3

5)2.

6)2.

Multiple choice questions: answers are provided following the reference list

Multiple choice questions: answers are provided following the reference list

  1. 1)

    Possible mechanisms for the renal injury of cystinosis include:

    1. 1.

      Renal tissue sensitivity to cystine accumulation

    2. 2.

      Expression of different splice isoforms of CTNS in the kidney

    3. 3.

      High sensitivity of the proximal tubule to apoptosis and energy depletion

    4. 4.

      All of the above

  2. 2)

    The most frequent cause of renal Fanconi syndrome in children is:

    1. 1.

      Renal transplant rejection

    2. 2.

      Heavy metal poisoning, i.e. lead

    3. 3.

      Oculocerebrorenal syndrome of Lowe

    4. 4.

      Cystinosis

    5. 5.

      Mitochondrial cytopathies

  3. 3)

    Which is not a common complication of NC in the first decade of life?

    1. 1.

      Corneal clouding due to cystine crystal accumulation

    2. 2.

      Hypothyroidism

    3. 3.

      Diabetes mellitus

    4. 4.

      Growth failure

    5. 5.

      Hypophosphatemic rickets

  4. 4)

    What percent of all childhood ESRD is contributed by NC:

    1. 1.

      About 10 %

    2. 2.

      Based on the longitudinal multi center studies, 5-10 %

    3. 3.

      Based on European Collaborative study, about 5 %

    4. 4.

      Close to 0 %

  5. 5)

    Normal values for leucocyte cystine content are:

    1. 1.

      Less than 1 nmol/half cystine/mg cell protein

    2. 2.

      Less than 0.2 nmol/half cystine/mg cell protein

    3. 3.

      No higher than 2 nmol/half cystine/mg cell protein

    4. 4.

      Non- detectable

  6. 6)

    The mechanism of action of cysteamine in targeting the basic defect in cystinosis involves:

    1. 1.

      Depleting cells by carrying cystine out of the cell into extracellular space

    2. 2.

      Interacting with cystine and forming cystine-cysteamine disulfide, and exporting this molecule from lysosome into cytosol

    3. 3.

      Restoring normal cystinosin function

    4. 4.

      Protecting cells from apoptosis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nesterova, G., Gahl, W.A. Cystinosis: the evolution of a treatable disease. Pediatr Nephrol 28, 51–59 (2013). https://doi.org/10.1007/s00467-012-2242-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-012-2242-5

Keywords

Navigation